
#PNS2027
Day(s)
:
Hour(s)
:
Minute(s)
:
Second(s)

Day(s)
:
Hour(s)
:
Minute(s)
:
Second(s)
Featured Mini-Symposia
As part of the 2027 PNS Annual Meeting, attendees may choose from two concurrent Mini-Symposia featuring in-depth exploration of emerging research, clinical advances, and evolving concepts in peripheral neuropathy. Each session brings together leading experts for focused presentations and discussion. Learn more about the topics and speakers below and plan your symposium experience.
Mini-Symposium A
Immuno-Oncology Associated Neuropathies: From Deep Phenotyping to Mechanisms and Precision Diagnostics and Therapeutics
Modern cancer therapy increasingly exposes peripheral nerves to overlapping toxic and immune injury. Cytotoxic chemotherapy, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs) and combination regimens can produce neuropathy, yet attribution determines whether anticancer therapy is modified and whether immunosuppression is initiated. This mini-symposium links oncology, translational neuroimmunology and peripheral nerve medicine. Dan Olson will discuss the transition from chemotherapy to immunotherapy and combinations, future neuropathy burden, referral thresholds and oncological trade-offs. Louisa Müller-Miny will examine why checkpoint release causes tissue-specific nerve injury, how acute inflammatory mechanisms can be distinguished from pre-existing or treatment-related toxic neuropathy, and how longitudinal fluid, tissue, single-cell and experimental approaches may enable prediction and prevention. Aisling Carr will address phenotype-first diagnosis, neurophysiology, biomarkers, standardized neuropathology, treatment and multidisciplinary services. The panel will define priorities for multicentre studies and future oncotherapeutic neurotoxicity surveillance worldwide, with relevance to prevention, survivorship and global access.

Daniel Olson, MD
University of Chicago, Chicago, IL, USA
Oncology in Transition: Neuropathy Risk, Attribution and Treatment Trade-Offs

Louisa Müller-Miny, MD
University Hospital Münster, Münster, Germany
From Checkpoint Release to Nerve Injury: Mechanistic Lessons from Immuno-Oncology

Aisling Carr, MD
Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK
Defining ICI-Associated Neuropathy: Current Clinical Phenotyping and Standardized Neuropathology
Mini-Symposium B
Precision Therapeutics for the Peripheral Nervous System: Targeting, Delivery, and Engineering
This session focuses on targeted strategies for treating pain and neuropathy. Talks will highlight recent advances in basic science, including with adeno-associated viral delivery vectors, engineered structural biology, and newly identified nerve-associated targets. The session will appeal to a broad scientific and clinical audience, with a focus that spans from molecular pathways to translational considerations and implications. Speakers include both tenure-track junior faculty and established senior investigators, and talks will be accessible and of interest to students, postdoctoral researchers, and faculty.

Afrooz Rashnonejad, PhD
The Ohio State University, Columbus, OH, USA
A Mutation-Agnostic AAV9 Knockdown-and-Replacement Strategy Rescues Disease Phenotypes in CMT1B Mice

Michael Caterina, MD, PhD
Johns Hopkins University, Baltimore, MD, USA
Genetically Based Targeting of Convergent Signaling Nodes to Treat Pathological Pain

Eric Villalón, PhD
Loyola University Chicago, Maywood, IL, USA
Molecular Targeting of the Neuronal Membrane Proteasome to Modulate Peripheral Sensory Signaling
Oncology in Transition: Neuropathy Risk, Attribution and Treatment Trade-Offs
Background Cancer treatment has moved from predominantly cytotoxic regimens toward immune checkpoint inhibition, antibody-drug conjugates and increasingly complex combinations. These therapies improve survival but expose peripheral nerves to distinct and sometimes simultaneous mechanisms of injury. In a patient receiving chemotherapy plus an ICI or ADC, assigning causality is clinically consequential: toxic neuropathy may require dose modification, whereas immune-mediated neuropathy may prompt treatment interruption and immunosuppression. Oncology perspective This presentation will place oncotherapeutic neuropathy in the context of the rapidly changing cancer-treatment landscape. It will consider how frequently peripheral neuropathy is encountered relative to idiopathic inflammatory neuropathies, how the burden could change as immunotherapies and combination regimens become more widely accessible globally, and which toxicities oncologists can safely manage without neurological input. Particular attention will be paid to when specialist neurology should be involved, whether referral should be restricted to severe grade 3/4 events, and how treatment mechanism, clinical tempo and competing causes influence attribution. Treatment trade-offs For patients receiving combination therapy, the central question is often not simply whether treatment should stop, but which component should be withheld and at what oncological cost. The talk will address interruption, de-escalation and rechallenge from the oncologist’s perspective, and how neurological diagnostic certainty changes risk-benefit decisions for cancer control. Conclusion Neuropathy attribution has become an oncological decision as much as a neurological one. Earlier cross-specialty assessment is likely to become increasingly important as treatment combinations expand and survivorship increases.
I am an Assistant Professor of Medicine at the University of Chicago Medicine and a clinical leader across melanoma, sarcoma, developmental therapeutics (phase 1), and solid tumor cell therapy programs. My work focuses on early-phase oncology drug development and cancer immunotherapy, with deep expertise in cutaneous oncology (including melanoma and other skin cancers) and sarcomas, as well as broader experience across advanced solid tumors through first-in-human and dose-expansion trials. I have led and supported clinical development across adoptive cell therapies—including tumor-infiltrating lymphocyte (TIL), TCR-engineered, and CAR-T platforms—as well as novel immuno-oncology targets (e.g., checkpoint/agonist approaches and innate immune agonists). I helped complete and report a practice-changing study of pembrolizumab plus low-dose ipilimumab after prior anti–PD-1 failure in advanced melanoma, and I serve on NCCN guideline panels for cutaneous melanoma, uveal melanoma, and bone cancers. I have also contributed to mechanistic immunology research around immune-related adverse events from immune checkpoint inhibitor therapy.
From Checkpoint Release to Nerve Injury: Mechanistic Lessons from Immuno-Oncology
Background Immune checkpoint inhibitors provide a human model of therapeutically induced loss of immune tolerance. Yet the mechanisms that determine why only a subset of patients develop neurological toxicity, why particular nervous-system compartments become targeted, and why peripheral nerve injury takes different clinical forms remain incompletely understood. Mechanistic framework and approaches This presentation will discuss complementary strategies to dissect ICI-associated neurotoxicity across scales. A key challenge is to distinguish a superimposed acute inflammatory neuropathy from pre-existing or cumulative toxic nerve injury caused by prior or concomitant anticancer treatment. Mechanistically, this requires identifying a new immune event rather than simply documenting axonal damage. Candidate mechanisms include release of pre-existing autoreactivity, tumour-nerve antigen cross-reactivity, bystander cytokine activation, failure of regulatory T cell control, tissue injury with antigen exposure, and selective recruitment or retention of activated lymphocytes within the peripheral nerve. These hypotheses can be addressed through paired blood/CSF analysis, single-cell transcriptomics with T- and B-cell receptor sequencing, soluble mediator and autoantibody profiling, and direct interrogation of affected nerve tissue using conventional pathology, immune-repertoire analysis and spatial approaches. Experimental models are required to test causality and to separate systemic checkpoint release from local tissue susceptibility. Illustrative translational observations Recent human studies support the concept that neurological irAEs can be characterized by compartment-specific immune activation rather than by a uniform systemic signature. As one example, our work identified activated and clonally expanded T-cell populations in affected neurological compartments, with CD8+ T-cell infiltration and local clonal expansion in sural nerve biopsies. In an experimental peripheral-nerve injury model, checkpoint inhibition amplified immune-cell recruitment, axonal injury and functional impairment.5 These findings will be used as an example of how fluid, tissue and model systems can be integrated rather than as the sole focus of the presentation. Conclusion Mechanistic studies should ultimately explain why ICI-associated neuropathies are not simply treatment-triggered versions of GBS or CIDP, how they differ from tumour-driven paraneoplastic neuropathies, and whether acute inflammatory deterioration can be separated from pre-existing toxic neuropathy at a biological level. Illustrative data from our programme – including compartment-specific T-cell activation, local clonal expansion in sural nerve and experimental checkpoint inhibition after nerve injury – will demonstrate how fluid, tissue and model systems can be connected.
Louisa Müller-Miny is a neurologist and clinician scientist at University Hospital Münster whose research focuses on neuroimmunology, peripheral neuropathies and cross-compartment immune profiling. Her work on neurological immune-related adverse events investigates checkpoint inhibitor-associated neurotoxicity using CSF and blood immune profiling, single-cell and immune-repertoire sequencing, nerve tissue and experimental models. Her contribution links the PNS field of inflammatory neuropathy to mechanistic questions surrounding how checkpoint inhibition produces acute immune-mediated nerve injury and how this can be distinguished from pre-existing or treatment-related toxic neuropathy.
Defining ICI-Associated Neuropathy: Current Clinical Phenotyping and Standardized Neuropathology
Background Immuno-oncology is a rapidly expanding and highly effective field of therapeutics which harnesses the power of the immune system to anti-cancer effect. Appreciation of the mechanism of action of the drug in use and its potential for on-target, off-cancer neurotoxic effect is important as the use of these drugs is now widespread in clinical practice. While cellular therapies (CAR-T) are associated with predominantly central nervous system impact and bi-and tri-specific result in atypical infection related to extreme B-cell depletion; the immune-checkpoint inhibitors cause predominantly neuromuscular immune-related adverse events via loss of T-cell control. While the toxic payload linked to anti-body drug conjugates have anti-microtubule toxicity targeting sensory nerves. It is therefore increasingly important to recognise and differentiate the particular clinical phenotype of the presenting neuropathy in order appropriately attribute causation and manage optimally ICI-associated Clinical phenotyping This presentation will review the neuropathy clinical spectrum of ICI and ADC-related neuropathies in particular. We propose a structured approach to neurological assessment, involving deep-phenotyping based on latency from ICI exposure, tempo of progression, motor, sensory, autonomic and cranial-nerve involvement, coexistence of myositis or neuromuscular-junction disease, paraclinical findings. treatment response, prognosis disability and outcome. We will highlight important differences between traditional autoimmune, paraneoplastic and toxic neuropathies considering the importance of nomenclature in the novel clinical area. The aim is to describe the phenotype first, rather than forcing all cases into conventional GBS or CIDP categories. Standardized neuropathology We will focus on the value of histopathological observations in recognising, evaluating immunopathogenesis and guiding treatment. Nerve biopsy can be uniquely informative in selected cases. A harmonized approach should build on established PNS nerve-biopsy standards and include predefined indications, standardized sampling and preservation of fixed, frozen and resin-embedded material, transverse and longitudinal assessment, semithin histology and a core immunohistochemical panel. Reporting should systematically capture axonal degeneration, demyelination/remyelination, endoneurial and perivascular inflammation, macrophage activation, vascular injury and the distribution and composition of immune infiltrates. Central review, digital pathology and prospective biobanking would additionally permit immune-repertoire, spatial and molecular analyses across centres. Conclusion Combining standardized clinical and neurophysiological phenotyping with reproducible neuropathological assessment offers a route toward a clinicopathological definition of ICI-associated neuropathy. Harmonized multicentre datasets are needed to determine which pathological patterns are disease-defining, which reflect severity or timing, and how tissue findings relate to biomarkers and treatment response.
Dr Carr was appointed as a consultant neurologist in the centre for Neuromuscular diseases, NHNN in 2015. She graduated with honours from Trinity College Dublin and Université François Rabelais, France and completed post-graduate training in medicine and Neurology in the Northern Ireland deanery. Her subspeciality expertise in neuromuscular diseases was developed through a Masters in myology, Sorbonne university Paris, a PhD in myasthenia epidemiology between Queen’s university Belfast and Oxford and a clinical fellowship in Peripheral Nerve in NHNN. Her current role involves clinical responsibilities in acquired and inflammatory peripheral nerve disease, immune-oncology neurotoxicity and Haemophagocytic Lymphohistiocytosis (HLH) neurology, with national services in the latter two areas. Her clinical research interests spans inflammatory neuropathy and understanding the toxicities of immune therapies. She is co-Editor in Chief of Practical Neurology, President elect of the British Peripheral Nerve Society, Association of Brisitsh Neurologists meeting secretary elect and executive committee member, associate editor for neuromuscular diseases JNNP, honorary associate professor ION/ UCL and sits on the board of the Inflammatory Neuropathy Consortium of the international Peripheral Nerve Society and Scientific committee member 2026/27.
A Mutation-Agnostic AAV9 Knockdown-and-Replacement Strategy Rescues Disease Phenotypes in CMT1B Mice
Dr. Rashnonejad’s talk will focus on work from her recently funded R01.
Afrooz Rashnonejad, MSc, PhD, is an Assistant Professor of Pediatrics at The Ohio State University College of Medicine and a Principal Investigator at the Jerry R. Mendell Center for Gene Therapy at Nationwide Children’s Hospital (NCH). Her research focuses on developing adeno-associated virus (AAV)-based gene therapies for neurological and neuromuscular diseases. As part of her doctoral work, she developed a prenatal gene therapy approach for Spinal Muscular Atrophy (SMA). She later completed her postdoctoral training at the Center for Gene Therapy at NCH, where she developed RNA-targeting therapies, including AAV-U7snRNA, AAV-CRISPR-Cas13, and RNAi- mediated gene therapies for FSHD. Her independent lab develops therapies for CMT1B peripheral neuropathy and nemaline myopathy by integrating RNAi, gene replacement, and patient iPSC-derived disease modeling. Dr. Rashnonejad served on multiple scientific committees, including chairing ASGCT’s New Investigator Committee and serving on the Musculoskeletal Cell and Gene Therapy Committee and the Prenatal Cell and Gene Therapy Committee. She was honored to receive the ASGCT Excellence in Research Award in two consecutive years, 2019 and 2020. Dr. Rashnonejad also serves on the scientific advisory boards of several patient foundations.
Genetically Based Targeting of Convergent Signaling Nodes to Treat Pathological Pain
Dr. Caterina’s talk will focus on new, unpublished work from his lab that fits into his extensive greater body of work.
Michael J. Caterina, MD, PhD is the Solomon H. Snyder Professor of Neurosurgery and Director of the Neurosurgery Pain Research Institute at Johns Hopkins University School of Medicine. He received his MD and PhD degrees from Johns Hopkins and carried out a postdoctoral fellowship at UCSF with Dr. David Julius before returning to Hopkins as a faculty member. His lab studies the cellular and molecular mechanisms that drive pathological inflammatory and neuropathic pain, using a wide range of in vitro and in vivo approaches. Their recent work has focused on exploiting synthetic biology to reengineer nociceptor signaling pathways, as a programmable, nonpharmacological approach to treating pathological pain.
Molecular Targeting of the Neuronal Membrane Proteasome to Modulate Peripheral Sensory Signaling
Dr. Villalón’s talk will focus on new data generated in his recently established lab at Loyola regarding a novel neuron associated membrane proteasome that he discovered.
Eric Villalón Landeros, PhD, is an Assistant Professor in the Department of Molecular Pharmacology and Neuroscience at Loyola University Chicago Stritch School of Medicine. He received his PhD from the University of Missouri and completed his postdoctoral training at Johns Hopkins University with Dr. Seth Margolis. His research focuses on understanding the molecular and cellular mechanisms that regulate peripheral sensory neuron function and somatosensory signaling. His work contributed to the discovery and characterization of the peripheral nervous system neuronal membrane proteasome (NMP), a specialized proteasome population, localized on the plasma membrane of sensory neurons, that regulates neuronal signaling. His laboratory combines molecular, cellular, and behavioral approaches to define how NMP activity shapes sensory neuron function and to explore its potential as a molecular target for modulating somatosensory signaling.